Olema Pharmaceuticals, Inc. Operating Income Loss

• Olema Pharmaceuticals, Inc. showed a decrease of -25.6% in Operating Income Loss from 2024 to 2025.
• This data is from Olema Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Olema Pharmaceuticals, Inc.'s Operating Income Loss has declined by 4,033.7%.
• Historical annual values: Fiscal year 2025: -$178.70 million | Fiscal year 2024: -$142.26 million | Fiscal year 2023: -$104.96 million | Fiscal year 2022: -$106.99 million | Fiscal year 2021: -$71.49 million | Fiscal year 2020: -$21.53 million | Fiscal year 2019: -$4.32 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026